For research teamsHelp me find a study
Back to all studies
TerminatedNCT01908192

Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, for schizophrenia

This study was terminated in the United States and in Taiwan. It is testing Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, for schizophrenia.

SchizophreniaDrugFrom 12 Years to 17 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT01908192. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

Check the official registry

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Taiwan · 3 sites
  • Chang Gung Memorial Hospital (Linkou)
    New Taipei City
    Site status: Not listed — confirm with the team
  • Chang Gung Memorial Hospital (Taipei)
    Taipei
    Site status: Not listed — confirm with the team
  • Veteran General Hospital Taipei
    Taipei
    Site status: Not listed — confirm with the team
United States · 20 sites
  • Harmonex Neuroscience Research
    Dothan, Alabama
    Site status: Not listed — confirm with the team
  • CiTrials
    Bellflower, California
    Site status: Not listed — confirm with the team
  • Renew Behavioral Health, Inc.
    Long Beach, California
    Site status: Not listed — confirm with the team
  • CiTrials
    Riverside, California
    Site status: Not listed — confirm with the team
  • Institute of Living/Hartford Hospital
    Hartford, Connecticut
    Site status: Not listed — confirm with the team
  • Children's National Health System
    Washington D.C., District of Columbia
    Site status: Not listed — confirm with the team
  • Premier Clinical Research Institute
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Medical Research Group of Central Florida
    Orange City, Florida
    Site status: Not listed — confirm with the team
  • Atlanta Center for Medical Research
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • John Hopkins University - Hugo W Moser Research Institute at Kennedy Krieger Inc.
    Baltimore, Maryland
    Site status: Not listed — confirm with the team
  • University of Massachusetts Medical School - Psychiatry Department
    Worcester, Massachusetts
    Site status: Not listed — confirm with the team
  • Michigan Clinical Research Institute
    Ann Arbor, Michigan
    Site status: Not listed — confirm with the team
  • University of Minnesota Medical Center - Department of Psychiatry
    Minneapolis, Minnesota
    Site status: Not listed — confirm with the team
  • Precise Research Centers
    Flowood, Mississippi
    Site status: Not listed — confirm with the team
  • Finger Lakes Clinical Research
    Rochester, New York
    Site status: Not listed — confirm with the team
  • University of Cincinnati - Dept. of Psychiatry and Behavioral Neuroscience
    Cincinnati, Ohio
    Site status: Not listed — confirm with the team
  • University Hospitals Case Medical Center
    Cleveland, Ohio
    Site status: Not listed — confirm with the team
  • Focus and Balance LLC
    San Antonio, Texas
    Site status: Not listed — confirm with the team
  • Pacific Institute of Medical Sciences
    Bothell, Washington
    Site status: Not listed — confirm with the team
  • Zain Research, LLC
    Richland, Washington
    Site status: Not listed — confirm with the team
In plain English

Key information made simple

What is this study testing?

This study is testing whether NaBen® may be useful for adolescents experiencing schizophrenia.

What would participation involve?

Participants may receive NaBen®, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Taiwan and in the United States.

Who is it mainly for?

This study appears to be mainly for adolescents with schizophrenia. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJune 2014
Recruitment status
Terminated
Enrollment listed in the registry
60
Sponsor
SyneuRx International (Taiwan) Corp
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States, Taiwan
Age range
From 12 Years to 17 Years
Official registry ID
NCT01908192
Official title
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT01908192. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving NaBen®, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 12 Years to 17 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by SyneuRx International (Taiwan) Corp, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.